Global Biosimilars/Follow-on-Biologics Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Forecast 2013-2020
Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020. Get Full Report at: http://www.researchbeam.com/biosimilars-market
Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020.
Get Full Report at:
http://www.researchbeam.com/biosimilars-market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
MARKET<br />
MARKET<br />
RESEARCH<br />
BEAM<br />
DEMAND<br />
SIZE<br />
RESEARCH<br />
FORECAST<br />
AND<br />
SIZE<br />
AND<br />
RESEARCH<br />
&<br />
RESEARCH<br />
RESEARCH<br />
MARKET<br />
DEMAND<br />
SIZE<br />
RESEARCH<br />
FORECAST<br />
AND<br />
SIZE<br />
AND<br />
RESEARCH<br />
&<br />
RESEARCH<br />
FORECAST<br />
<str<strong>on</strong>g>Global</str<strong>on</strong>g> <str<strong>on</strong>g>Biosimilars</str<strong>on</strong>g>/<str<strong>on</strong>g>Follow</str<strong>on</strong>g>-<strong>on</strong>-<strong>Biologics</strong><br />
<strong>Market</strong> (Technology, Types, Applicati<strong>on</strong>s,<br />
Services and Geography) <strong>2013</strong>-<strong>2020</strong><br />
TELEPHONE: +1 (855) 711-1555<br />
E-MAIL: sales@researchbeam.com
Report Overview<br />
<str<strong>on</strong>g>Biosimilars</str<strong>on</strong>g> or follow-<strong>on</strong>-biologics are the “copied” versi<strong>on</strong> of<br />
reference biologics, which are protected by intellectual rights<br />
that will expire so<strong>on</strong>. Patent expirati<strong>on</strong> is the major driving<br />
factor of the biosimilars market. Most of the blockbuster<br />
patents will expire by the end of 2014, which would provide a<br />
competitive edge to local pharmaceutical manufacturers over<br />
the global players. For instance, patents for insulin glargine will<br />
expire by the end of this year, which would give an opportunity<br />
for the growth of insulin biosimilars market. <str<strong>on</strong>g>Global</str<strong>on</strong>g><br />
biosimilars/follow-<strong>on</strong>-biologics market accounted for $1,358<br />
milli<strong>on</strong> in <strong>2013</strong> and it is anticipated to generate $35,032 milli<strong>on</strong><br />
by <strong>2020</strong>, growing at a CAGR of 60.8% from 2014 to <strong>2020</strong>.<br />
Browse Complete Study Report at:<br />
http://www.researchbeam.com/biosimilars-market
Report Overview<br />
Regulati<strong>on</strong>s for biosimilars plays a vital role in maintaining the<br />
viability and balance between original and biosimilar products.<br />
Various regulatory authorities, namely EMA and the U.S. FDA<br />
are actively regulating the biosimilars market. Regulati<strong>on</strong>s in the<br />
European uni<strong>on</strong> are c<strong>on</strong>sidered benchmark around the world,<br />
as the guidelines proposed are most stringent for validati<strong>on</strong> and<br />
commercializati<strong>on</strong> of biosimilars. High profitability is the<br />
attractive aspect that is enticing companies to invest in the<br />
biosimilars industry.<br />
Geographically, <str<strong>on</strong>g>Biosimilars</str<strong>on</strong>g> market is segmented into North<br />
America, Europe, Asia-Pacific and LAMEA. Due to favorable<br />
regulatory policies designed by the European Medical<br />
Associati<strong>on</strong>, the European market has been maximizing <strong>on</strong> the<br />
biosimilars market. Asia-Pacific and LAMEA market would<br />
witness a substantial rise in the use of biosimilars, as the<br />
demand for cost effective treatment is growing due to the<br />
prevalence of chr<strong>on</strong>ic diseases.
Report Overview<br />
Key Benefits<br />
• The study is segmented in a strategic divisi<strong>on</strong>s to gain<br />
deeper insights into the market dynamics and understand<br />
the competitive envir<strong>on</strong>ment of the overall market<br />
• Financial market forecast is provided for the next eight<br />
years by c<strong>on</strong>sidering <strong>2013</strong> as the base year<br />
• Comprehensive and quantitative data about changing<br />
market trends, intensifying competiti<strong>on</strong> and opportunities in<br />
biosimilars market are provided to make better business<br />
decisi<strong>on</strong>s<br />
• Porter’s Five Forces model and SWOT analysis of the<br />
overall market is provided to help stakeholders gain strategic<br />
insights of the market<br />
• Deep dive analysis of key market players and strategies<br />
adopted by them are expounded to provide valuable<br />
informati<strong>on</strong> <strong>on</strong> the top c<strong>on</strong>tenders in the market<br />
• Identificati<strong>on</strong> of key investment pockets for the biosimilars<br />
market is strategically dealt to assist the stakeholders
Report Overview<br />
Key Deliverables<br />
<str<strong>on</strong>g>Global</str<strong>on</strong>g> biosimilars/follow-<strong>on</strong>-biologics market is categorized into<br />
technology, product types, applicati<strong>on</strong>s, services and<br />
geography.<br />
MARKET BY TECHNOLOGY<br />
• M<strong>on</strong>ocl<strong>on</strong>al Antibodies (MAb) Technology<br />
• Recombinant DNA Technology (rDNA technology)<br />
• Nuclear magnetic res<strong>on</strong>ance (NMR) technology<br />
• Chromatography<br />
• Electrophoresis<br />
• Mass Spectrometry<br />
• Western Blotting<br />
• Bioassay<br />
Enquire About Report: http://www.researchbeam.com/biosimilarsmarket/enquire-about-report
Tables of C<strong>on</strong>tents<br />
CHAPTER 1 INTRODUCTION<br />
1.1 Key Benefits<br />
1.2 Key <strong>Market</strong> Segment<br />
1.3 Key Audiences<br />
1.3.1 Research Methodology<br />
1.3.2 Primary Research<br />
1.3.3 Sec<strong>on</strong>dary Research<br />
1.3.4 Analyst tools and models<br />
CHAPTER 2 EXECUTIVE SUMMARY<br />
2.1 CXO perspective<br />
2.2 <strong>Market</strong> bey<strong>on</strong>d: what to expect by 2025<br />
2.2.1 Moderate growth scenario<br />
2.2.2 Rapid growth scenario<br />
2.2.3 Diminishing growth scenario
Similar <strong>Market</strong> Reports<br />
• Critical Pharmaceuticals Limited - Pharmaceuticals &<br />
Healthcare - Deals and Alliances Profile<br />
http://www.researchbeam.com/critical-pharmaceuticalslimited-pharmaceuticals-and-healthcare-deals-and-alliancesprofile-market<br />
• Bristol-Myers Squibb <strong>Company</strong> (BMY) - Financial and<br />
Strategic SWOT <strong>Analysis</strong> Review<br />
http://www.researchbeam.com/bristol-myers-squibb-companybmy-financial-and-strategic-swot-analysis-review-market<br />
• Metastatic Hepatocellular Carcinoma (HCC) - Pipeline<br />
Review, H1 2015<br />
http://www.researchbeam.com/metastatic-hepatocellularcarcinoma-hcc-pipeline-review-h1-2015-market
C<strong>on</strong>tact<br />
Visit us at :<br />
http://www.researchbeam.com/biosimilars-market<br />
TELEPHONE: +1 (855) 711-1555<br />
E-MAIL: help@researchbeam.com<br />
5933 NE Win Sivers Drive,<br />
#205, Portland, OR 97220<br />
United States
Change language